Literature DB >> 19935701

The tumor suppressor ING3 is degraded by SCF(Skp2)-mediated ubiquitin-proteasome system.

G Chen1, Y Wang, M Garate, J Zhou, G Li.   

Abstract

The inhibitor of growth family member 3 (ING3) has been shown to modulate transcription, cell cycle control and apoptosis. We previously reported that nuclear ING3 expression was remarkably reduced in melanomas, which correlated with a poorer patient survival, suggesting that decreased ING3 expression may be associated with melanoma progression. However, the mechanism of diminished ING3 expression in melanoma is not clear. Here we show that ING3 level was decreased in metastatic melanoma cells because of a rapid degradation. Furthermore, we showed that ING3 undergoes degradation through the ubiquitin-proteasome pathway. ING3 physically interacts with subunits of E3 ligase Skp1-Cullin-F-box protein complex (SCF complex). Knockdown of F-box protein S-phase kinase-associated protein 2 (Skp2) reduces the ubiquitination of ING3 and significantly stabilizes ING3 in melanoma cells. In addition, lysine 96 residue is essential for ING3 ubiquitination as its mutation to arginine dramatically abrogated ING3 degradation. Disruption of ING3 degradation stimulated ING3-induced G1 cell-cycle arrest and enhanced ultraviolet-induced apoptosis. Taken together, our data show that ING3 is degraded by the ubiquitin-proteasome pathway through the SCF(Skp2) complex and interruption of ING3 degradation enhances the tumor-suppressive function of ING3, which provides a potential cancer therapeutic approach by interfering ING3 degradation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19935701     DOI: 10.1038/onc.2009.424

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

1.  Downregulation of inhibitor of growth 3 is correlated with tumorigenesis and progression of hepatocellular carcinoma.

Authors:  Meiling Lu; Fei Chen; Qinwan Wang; Kesheng Wang; Qiuhui Pan; Xin Zhang
Journal:  Oncol Lett       Date:  2012-04-19       Impact factor: 2.967

2.  Cullins and cancer.

Authors:  Jennifer Lee; Pengbo Zhou
Journal:  Genes Cancer       Date:  2010-07

Review 3.  Small molecule therapeutics targeting F-box proteins in cancer.

Authors:  Yuan Liu; Rama K Mallampalli
Journal:  Semin Cancer Biol       Date:  2015-09-30       Impact factor: 15.707

Review 4.  Inhibitor of growth tumor suppressors in cancer progression.

Authors:  Brad Piche; Gang Li
Journal:  Cell Mol Life Sci       Date:  2010-03-02       Impact factor: 9.261

Review 5.  INGs are potential drug targets for cancer.

Authors:  Runyun Zhang; Jianhua Jin; Juanjuan Shi; Yongzhong Hou
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-20       Impact factor: 4.553

6.  Overexpression of ING3 is associated with attenuation of migration and invasion in breast cancer.

Authors:  Huimeng Li; Hengyu Zhang; Xin Tan; Dequan Liu; Rong Guo; Maohua Wang; Yiyin Tang; Kai Zheng; Wenlin Chen; Hongwan Li; Mingjian Tan; Ke Wang; Rui Liu; Shicong Tang
Journal:  Exp Ther Med       Date:  2021-05-02       Impact factor: 2.447

7.  Cytoplasmic Skp2 expression is increased in human melanoma and correlated with patient survival.

Authors:  Guangdi Chen; Yabin Cheng; Zhizhong Zhang; Magdalena Martinka; Gang Li
Journal:  PLoS One       Date:  2011-02-28       Impact factor: 3.240

8.  Downregulated inhibitor of growth 3 (ING3) expression during colorectal carcinogenesis.

Authors:  Wen-feng Gou; Hong-zhi Sun; Shuang Zhao; Zhe-feng Niu; Xiao-Yun Mao; Yasuo Takano; Hua-chuan Zheng
Journal:  Indian J Med Res       Date:  2014-04       Impact factor: 2.375

9.  A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.

Authors:  Shailender Bhatia; Anna C Pavlick; Peter Boasberg; John A Thompson; George Mulligan; Michael D Pickard; Hélène Faessel; Bruce J Dezube; Omid Hamid
Journal:  Invest New Drugs       Date:  2016-04-08       Impact factor: 3.850

10.  E3 ubiquitin ligase Nedd4 inhibits AP-1 activity and TNF-α production through targeting p38α for polyubiquitination and subsequent degradation.

Authors:  Qingjun Liu; Shihui Zhang; Gan Chen; Hong Zhou
Journal:  Sci Rep       Date:  2017-07-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.